DOTATATE

Target SSTR 2/3Class Peptide (somatostatin analogue, DOTA chelator)Other names oxodotreotide, DOTA-[Tyr³]octreotate

68ongoing trials

5radiolabelled forms

4approved products

3,170publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula: C65H90N14O19S2
Molar mass (g/mol): 1,435.6
Exact mass (Da): 1,434.5948
XLogP: -9.3
H-bond donors: 17
H-bond acceptors: 26
Rotatable bonds: 26
Heavy atoms: 100
InChIKey: QVFLVLMYXXNJDT-CSBVGUNJSA-N
PubChem record: CID 11170867 ↗
IUPAC name: (2S,3R)-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-3-phenyl-2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-hydroxybutanoic acid
SMILES: C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)O

Radiolabelled forms

Form	Use	Molar mass (labelled form)	Ongoing trials	Most advanced phase	Approval
[¹⁷⁷Lu]Lu-DOTATATE Syntheses and QC ↗	Therapy	1,609.5	49	Phase 3	Lutathera US EU FR JP, Bexlutry US
[²²⁵Ac]Ac-DOTATATE Syntheses and QC ↗	Therapy	—	5	Phase 3	—
[²¹²Pb]Pb-DOTAMTATE	Therapy	—	2	Phase 2	—
[⁶⁸Ga]Ga-DOTATATE Syntheses and QC ↗	Imaging	1,500.5	11	Phase 3	DOTATATE / DOTATOC (Netspot, SomaKit TOC…) US EU FR
[⁶⁴Cu]Cu-DOTATATE Syntheses and QC ↗	Imaging	1,497.5	2	Phase 2	Detectnet US

Ongoing trials · 68Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

Trial	Phase	Status	Sponsor	Countries
NETTER-3 · [177Lu]DOTATATENCT06784752 · Gastroenteropancreatic NETs	Phase 3	Recruiting	Novartis Pharmaceuticals	12
ACTION-1 · RYZ101 ([225Ac]Ac-DOTATATE)NCT05477576 · Gastroenteropancreatic NETs	Phase 3	Active, not recruiting	RayzeBio, Inc.	8
NETTER-2 · [177Lu]DOTATATENCT03972488 · Gastroenteropancreatic NETs	Phase 3	Active, not recruiting	Advanced Accelerator Applications	9
[177Lu]DOTATATENCT05459844 · Gastroenteropancreatic NETs	Phase 3	Active, not recruiting	Sinotau Pharmaceutical Group	1
[177Lu]DOTATATENCT05884255 · Gastroenteropancreatic NETs	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	1
[177Lu]DOTATATENCT07057622 · NETs and neuroendocrine carcinomas (other)	Phase 3	Recruiting	HTA Co., Ltd.	1
PReCedeNT · [177Lu]DOTATATENCT07185672 · Gastroenteropancreatic NETs	Phase 3	Recruiting	Tata Memorial Hospital	1
[177Lu]DOTATATE2024-518236-36-00 · Gastroenteropancreatic NETs	Phase 3	Recruiting	Philipps-Universitaet Marburg	1
RIALTO · [177Lu]DOTATATENCT06878664 · Gastroenteropancreatic NETs	Phase 3	Recruiting	Grupo Espanol de Tumores Neuroendocrinos	2
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT07119242 · NETs and neuroendocrine carcinomas (other)	Phase 3	Active, not recruiting	HTA Co., Ltd.	1
[177Lu]DOTATATENCT06398444 · NETs and neuroendocrine carcinomas (other)	Phase 3	Recruiting	Sinotau Pharmaceutical Group	1
LUMEN-1 · [177Lu]DOTATATENCT06326190 · Meningioma	Phase 2	Recruiting	European Organisation for Research and Treatment of Cancer - EORTC	6
[177Lu]DOTATATENCT05773274 · Gastroenteropancreatic NETs	Phase 2	Recruiting	National Cancer Institute (NCI)	2
[177Lu]DOTATATENCT04665739 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT05142696 · Small-cell lung cancer	Phase 2	Active, not recruiting	Novartis Pharmaceuticals	12
MOMENTUM-1 · [177Lu]DOTATATENCT06955169 · Meningioma	Phase 2	Recruiting	RTOG Foundation, Inc.	1
[177Lu]DOTATATENCT05724108 · NETs and neuroendocrine carcinomas (other)	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT05247905 · Gastroenteropancreatic NETs	Phase 2	Active, not recruiting	Alliance for Clinical Trials in Oncology	1
LUMOD-ID · [177Lu]DOTATATENCT06395402 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	University of Iowa	1
ReLUTH · [177Lu]DOTATATENCT04954820 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	Institut du Cancer de Montpellier - Val d'Aurelle	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT04888481 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	University of Alberta	1
[177Lu]DOTATATENCT03206060 · Pheochromocytoma / paraganglioma	Phase 2	Recruiting	National Cancer Institute (NCI)	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT02019706 · Adrenal	Phase 2	Recruiting	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1
P-PRRT · [177Lu]DOTATATENCT02754297 · NETs and neuroendocrine carcinomas (other)	Phase 2	Active, not recruiting	CHU de Quebec-Universite Laval	1
[177Lu]DOTATATENCT05691465 · Prostate – other	Phase 2	Recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT04082520 · Meningioma	Phase 2	Recruiting	Mayo Clinic	1
[177Lu]DOTATATENCT05278208 · Meningioma	Phase 2	Recruiting	Nationwide Children's Hospital	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT07284589 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	Akiva Mintz	1
[177Lu]DOTATATENCT03971461 · Meningioma	Phase 2	Active, not recruiting	NYU Langone Health	1
TRACY-1 · RYZ101 ([225Ac]Ac-DOTATATE)NCT06590857 · Breast	Phase 2	Recruiting	RayzeBio, Inc.	3
NETTER-P · [177Lu]DOTATATENCT04711135 · Pheochromocytoma / paraganglioma	Phase 2	Active, not recruiting	Advanced Accelerator Applications	5
[212Pb]DOTATATENCT06427798 · Pheochromocytoma / paraganglioma	Phase 2	Recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT02236910 · NETs and neuroendocrine carcinomas (other)	Phase 2	Active, not recruiting	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	1
[177Lu]DOTATATENCT04086485 · Gastroenteropancreatic NETs	Phase 2	Recruiting	National Cancer Institute (NCI)	1
GoTHAM · [177Lu]DOTATATENCT04261855 · NETs and neuroendocrine carcinomas (other)	Phase 2	Active, not recruiting	Melanoma and Skin Cancer Trials Limited	1
[68Ga]Ga-DOTA-TATE/TOC/NOC2024-516156-18-00 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	Rigshospitalet	1
RYZ101 ([225Ac]Ac-DOTATATE)NCT07150806 · Meningioma	Phase 2	Recruiting	Joshua Palmer	1
LuDO-N · [177Lu]DOTATATENCT04903899 · Neuroblastoma	Phase 2	Recruiting	Jakob Stenman	5
iPRRT · [177Lu]DOTATATENCT05583708 · NETs and neuroendocrine carcinomas (other)	Phase 2	Recruiting	Weill Medical College of Cornell University	1
[177Lu]DOTATATENCT06121271 · Pheochromocytoma / paraganglioma	Phase 2	Not yet recruiting	University College, London	0
[177Lu]DOTATATENCT04529044 · Breast	Phase 2	Recruiting	OHSU Knight Cancer Institute	1
LUTARTERIAL · [177Lu]DOTATATENCT04837885 · Gastroenteropancreatic NETs	Phase 2	Recruiting	University Hospital, Bordeaux	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT04559217 · Neuroblastoma	Phase 2	Recruiting	Centre de recherche du Centre hospitalier universitaire de Sherbrooke	1
ELUMEN · [177Lu]DOTATATENCT06126588 · Meningioma	Phase 2	Recruiting	Central Hospital, Nancy, France	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT07835906 · NETs and neuroendocrine carcinomas (other)	Phase 2	Not yet recruiting	Peking Union Medical College Hospital	1
LUPARPED · [177Lu]DOTATATENCT06607692 · Neuroblastoma	Phase 2	Recruiting	Fundación de investigación HM	1
[177Lu]DOTATATENCT05109728 · Brain (glioma, medulloblastoma…)	Phase 1	Active, not recruiting	Novartis Pharmaceuticals	5
[212Pb]DOTATATENCT06479811 · Neuroblastoma	Phase 1	Recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT04234568 · Gastroenteropancreatic NETs	Phase 1	Active, not recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT05687123 · Gastroenteropancreatic NETs	Phase 1	Recruiting	National Cancer Institute (NCI)	2
[177Lu]DOTATATENCT04750954 · Gastroenteropancreatic NETs	Phase 1	Active, not recruiting	National Cancer Institute (NCI)	1
[177Lu]DOTATATENCT06663072 · Gastroenteropancreatic NETs	Phase 1	Recruiting	University of Chicago	1
[177Lu]DOTATATENCT04544098 · Gastroenteropancreatic NETs	Phase 1	Active, not recruiting	Memorial Sloan Kettering Cancer Center	1
[225Ac]DOTATATENCT06732505 · NETs and neuroendocrine carcinomas (other)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	1
PARLuNET · [177Lu]Lu-DOTATATE + talazoparibNCT05053854 · NETs and neuroendocrine carcinomas (other)	Phase 1	Recruiting	Peter MacCallum Cancer Centre, Australia	1
LANTana · [177Lu]DOTATATENCT05178693 · NETs and neuroendocrine carcinomas (other)	Phase 1	Recruiting	Imperial College London	1
PRRT-PARPi · [177Lu]Lu-DOTATATE + olaparibNCT05870423 · NETs and neuroendocrine carcinomas (other)	Phase 1	Recruiting	Erasmus Medical Center	1
[225Ac]DOTATATENCT07413042 · Small-cell lung cancer	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	1
[68Ga]Ga-DOTA-TATE/TOC/NOCNCT04040088 · Neuroblastoma	Phase 1	Active, not recruiting	Mayo Clinic	1
[177Lu]DOTATATENCT07150546 · NETs and neuroendocrine carcinomas (other)	Phase 1	Recruiting	Emory University	1

Other trials listing it among the interventions (comparator, associated scan) · 1

MIBG and analogues (innervation, neural crest)NCT05069220 · Neuroblastoma

Phase 1

Recruiting

Peking Union Medical College Hospital

Published results · 4

2026-10	ETCTN 10388 · mixedCombination with an oral radiosensitiser is feasible, but haematological toxicity is marked (grade 4 neutropenia in 7 patients, grade ≥ 3 events in 77%).	Clin Cancer Res ↗
2026-09	Pembrolizumab + PRRT · mixedPilot study in grade 2-3 NETs (26 patients): 35% response rate, progression-free survival of 13.3 months, but serious adverse events in more than half of the patients.	Clin Cancer Res ↗
2026-08	NETTER-2 (sous-groupes) · positiveIn first-line grade 2-3 GEP-NETs, the benefit of Lutathera holds whatever the grade and primary site (HR between 0.23 and 0.34).	EClinicalMedicine ↗
2026-06	OCLURANDOM · positiveFrench randomized (non-comparative) trial in pretreated pancreatic NETs: 80.5% progression-free at 12 months with Lutathera vs 41.9% with sunitinib, and better quality of life. Late effects are reported and should be weighed for subsequent lines.	Lancet Oncol ↗

PublicationsAll publications in PubMed ↗

3,170 publications in PubMed for the query below; the most recent:

DOTATATE[tiab] OR oxodotreotide[tiab] OR "DOTA-TATE"[tiab]

Targeted radionuclide-drug conjugates: Current status and perspectives Eur J Med Chem, 2026
Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing (68)Gallium-DOTATATE positron emission tomography J Neuroendocrinol, 2026
Intracranial phosphaturic mesenchymal tumor mimicking meningioma and causing tumor-induced osteomalacia: a case report JBMR Plus, 2026
Unusual paraneoplastic thrombocytosis in small bowel neuroendocrine tumor responding to (177)Lu-DOTATATE JCEM Case Rep, 2026
68Ga-DOTATATE PET/CT Detection of Hypertrophic Osteoarthropathy in a Pediatric Patient With Neuroblastoma Following Anti-GD2 Immunotherapy Clin Nucl Med, 2026
A case of metastasectomy following multiple courses of radionuclide therapy for distant metastatic pheochromocytoma JCEM Case Rep, 2026
Metastasis of lung carcinoma in a pheochromocytoma JCEM Case Rep, 2026
One Tracer, Whole Syndrome: CAIX-Targeted PET Unmasks the Multisystem Tumor Landscape of Von Hippel-Lindau Disease Clin Nucl Med, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

DOTATATE. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/dotatate/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.